GO
Loading...

Vertex Pharmaceuticals Inc

More

  • Regulatory "Risky Business" for Pharma & Biotech Monday, 28 Apr 2008 | 11:56 AM ET
    Risky Business

    It's a big day for pipeline progress...or not. Late Friday, Merck and Schering-Plough announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...

  • Options Look to Hepatitis-C Payoff Thursday, 3 Apr 2008 | 9:40 AM ET

    Options activity is picking up in Johnson & Johnson stock. Why?

  • Vytorin Battle Pits Merck/Schering-Plough Vs Pfizer Tuesday, 1 Apr 2008 | 11:03 AM ET

    Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed. Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero.

  • Pops & Drops: Fortune Brands, Northwest... Monday, 31 Mar 2008 | 7:00 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of Fortune Brands and Northwest Airlines popped while Thornburg Mortgage  and Cal-Maine Foods dropped.

  • Major Indices Teetering on Breaking Losing Streaks Monday, 31 Mar 2008 | 9:47 AM ET

    The Dow, S&P and Nasdaq are just points away from breaking their monthly losing streaks at 4 straight months of losses. Here's what they would need to rally today to have their first positive month since October:

  • Merck, Vertex MK-0457 Trials Halted on Heart Risk Tuesday, 20 Nov 2007 | 9:01 PM ET

    Vertex Pharmaceuticals said Merck & Co halted enrollment on trials of their investigational leukemia drug MK-0457 due to a potential heart safety issue in one patient.

  • Vertex In The "Vortex" Over Hepatitis C Test Results Friday, 2 Nov 2007 | 12:04 PM ET
    Vertex

    There's a flurry of selling going on this morning in shares of the biopharma Vertex Pharmaceuticals. Overnight the embargo lifted on the long awaited results of the company's mid-stage test on a new type of Hepatitis C drug. Two studies show that six months out 60% and 65% of patients had no detectable virus in their blood.

  • Biogen Idec: First Of A Biotech Buying Binge? Monday, 15 Oct 2007 | 12:52 PM ET

    For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.

  • Quarterly earnings reports and new drug trial data were some of the catalysts behind the most actively traded stocks on Wednesday.

  • Medical Therapy Stocks Prescribed by Analyst Friday, 18 May 2007 | 11:25 AM ET

    More than 4.1 million Americans live with hepatitis C, a viral infection of the liver. That's why Jason Kolbert, a biotechnology analyst at Susquehanna Financial Group, advised "Squawk Box" viewers to stock up on therapy stocks.

  • Sudden Death Tuesday, 17 Apr 2007 | 6:57 PM ET

    PDL BioPharma, United Online, Vertex Pharma: In under a minute, Cramer's got calls on all three.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • It's Time for the Lightning Round! Thursday, 12 Apr 2007 | 11:09 AM ET

    New York Stock Exchange, Airgas, CMGI and many more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Stocks Close Modestly Higher Ahead of Fed Meeting Monday, 11 Dec 2006 | 4:55 PM ET

    Stocks posted modest gains across the board--with financial, technology and energy stocks showing strength.

Most Popular Video

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.